drugset / Trial / NCT07518147

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

NCT07518147 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M05D1 in patients with Claudin (CLDN) 18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received prior first-line treatment.

Timeline

Start
2026-05-15
Primary completion
2029-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BL-M05D1 Unknown — Intravenous
Comparator Docetaxel Small molecule — Intravenous
Comparator Irinotecan Small molecule — Intravenous
Comparator Paclitaxel Small molecule — Intravenous